Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
CytomX Therapeutics (CTMX) PT Raised to $37 at Wedbush Amid Amgen Collaboration
October 4, 2017 6:35 AM EDTWedbush analyst Robert Driscoll raised his price target on CytomX Therapeutics (NASDAQ: CTMX) to $37.00 (from $26.00) while maintaining a Outperform rating after the company added Amgen to its partner list with a new bispecifics collaboration.
Driscoll views bispecifics as an ideal application of the masking... More
